<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664116</url>
  </required_header>
  <id_info>
    <org_study_id>DHC-002</org_study_id>
    <nct_id>NCT02664116</nct_id>
  </id_info>
  <brief_title>IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine</brief_title>
  <official_title>IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will be conducted to see if the oral drug Cambia is as effective in relieving
      severe migraine headaches as the injectable drug ketorolac.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of severe migraine often requires a patient office visit or treatment in the ER
      or urgent care setting. This is due to the minimal efficacy of PO treatments once migraine is
      severe, and therefore the need for parenteral treatments. IM Ketorolac is one mainstay of
      parenteral treatment. There is an unmet need for effective at-home treatment regimens for
      severe migraine. Despite FDA approval of Cambia for acute migraine treatment, insurance is
      reticent to cover the treatment due to higher cost in comparison to generic diclofenac
      tablets, despite superior efficacy of Cambia in comparison to generic diclofenac tablets
      (Diener, Cephalalgia 2006). One objective of this study would be to provide rationale to
      justify the insurance coverage of this treatment in comparison to generic tablets, because at
      home treatment is less costly than office visit or emergency department visit to receive IM
      ketorolac.

      A previous study of Cambia demonstrated that this formulation of diclofenac potassium for
      oral solution is effective in reducing pain intensity within 30 minutes, which may be related
      to the 15-minute Tmax associated with this formulation. The rapid-onset benefits were
      sustained through 24 hours post-treatment (Lipton, Cephalalgia 2010)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief, 0-3 scale</measure>
    <time_frame>Change from baseline pain rating at 5, 10, 15, 30, and 60 minutes post intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain free response, 0-3 scale</measure>
    <time_frame>2 hours post intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained pain free response, 0-3 scale</measure>
    <time_frame>24 hours post intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in severity of migraine associated symptoms</measure>
    <time_frame>5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention</time_frame>
    <description>Disability, Nausea, Photophonia/phonophobia self reported using a 0-3 rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to function</measure>
    <time_frame>24 hours post intervention</time_frame>
    <description>Severity, Disability, Nausea, Photophonia/phonophobia self reported as 0 on 0-3 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Cambia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac postassium powder for oral solution and placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketorolac intramuscular injection and placebo oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac postassium powder for oral solution and placebo injection</intervention_name>
    <description>Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose</description>
    <arm_group_label>Cambia</arm_group_label>
    <other_name>Cambia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac intramuscular injection and placebo oral solution</intervention_name>
    <description>ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose</description>
    <arm_group_label>ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet IHS criteria for migraine

          -  Age 18 to 65

          -  At least 2 migraine attacks per month

          -  Able to give written consent

          -  Willing to complete the entire course of the study

          -  Current headache duration greater than or equal to 36 hours

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Significant medical or psychiatric disease

          -  History of gastritis, gastric ulcer, GI bleed

          -  Renal insufficiency

          -  Hepatic insufficiency

          -  History of opioid dependence within the last 10 years or currently

          -  Any current or prior use of DICLOFENAC POTASSIUM POWDER FOR ORAL SOLUTION (CAMBIA)

          -  Past allergic reaction to DICLOFENAC or other NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Rubenstein Engel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Rubenstein Engel, MD</last_name>
    <phone>858-554-8887</phone>
    <email>Engel.EmilyRubenstein@scrippshealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Rubenstein Engel, M.D.</last_name>
      <phone>858-554-8887</phone>
      <email>Engel.EmilyRubenstein@scrippshealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Factor SA, Jankovic J. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014 Oct 7;83(15):1388-9. doi: 10.1212/01.wnl.0000455698.16732.0a.</citation>
    <PMID>25288700</PMID>
  </reference>
  <reference>
    <citation>Garnock-Jones KP. Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine. CNS Drugs. 2014 Aug;28(8):761-8. doi: 10.1007/s40263-014-0186-y. Review.</citation>
    <PMID>25034250</PMID>
  </reference>
  <reference>
    <citation>Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D, Bijur PE, Gallagher EJ. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014 Mar 18;82(11):976-83. doi: 10.1212/WNL.0000000000000223. Epub 2014 Feb 12.</citation>
    <PMID>24523483</PMID>
  </reference>
  <reference>
    <citation>Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013 Feb;53(2):277-87. doi: 10.1111/head.12009. Epub 2013 Jan 8. Review.</citation>
    <PMID>23298250</PMID>
  </reference>
  <reference>
    <citation>Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, Saper JR. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010 Nov;30(11):1336-45. doi: 10.1177/0333102410367523. Epub 2010 Apr 7.</citation>
    <PMID>20959428</PMID>
  </reference>
  <reference>
    <citation>Duarte C, Dunaway F, Turner L, Aldag J, Frederick R. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med. 1992 Sep;21(9):1116-21.</citation>
    <PMID>1514724</PMID>
  </reference>
  <reference>
    <citation>Orr SL, Aubé M, Becker WJ, Davenport WJ, Dilli E, Dodick D, Giammarco R, Gladstone J, Leroux E, Pim H, Dickinson G, Christie SN. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015 Mar;35(3):271-84. doi: 10.1177/0333102414535997. Epub 2014 May 29. Review.</citation>
    <PMID>24875925</PMID>
  </reference>
  <reference>
    <citation>Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review.</citation>
    <PMID>25600718</PMID>
  </reference>
  <reference>
    <citation>Diener HC, Montagna P, Gács G, Lyczak P, Schumann G, Zöller B, Mulder LJ, Siegel J, Edson K. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006 May;26(5):537-47.</citation>
    <PMID>16674762</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Emily Rubenstein Engel</investigator_full_name>
    <investigator_title>Associate Director, Dalessio Headache Center, Scripps Clinic</investigator_title>
  </responsible_party>
  <keyword>Severe Migraine Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Patient Data will not be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

